JPH0480003B2 - - Google Patents
Info
- Publication number
- JPH0480003B2 JPH0480003B2 JP55178199A JP17819980A JPH0480003B2 JP H0480003 B2 JPH0480003 B2 JP H0480003B2 JP 55178199 A JP55178199 A JP 55178199A JP 17819980 A JP17819980 A JP 17819980A JP H0480003 B2 JPH0480003 B2 JP H0480003B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- hair growth
- whey
- placenta
- conventional method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002826 placenta Anatomy 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 19
- 239000005862 Whey Substances 0.000 claims description 13
- 102000007544 Whey Proteins Human genes 0.000 claims description 13
- 108010046377 Whey Proteins Proteins 0.000 claims description 13
- 238000007796 conventional method Methods 0.000 claims description 12
- 230000003779 hair growth Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 235000013861 fat-free Nutrition 0.000 claims description 7
- 239000000419 plant extract Substances 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 235000008160 pyridoxine Nutrition 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000011677 pyridoxine Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940042585 tocopherol acetate Drugs 0.000 description 7
- 229940011671 vitamin b6 Drugs 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 235000019192 riboflavin Nutrition 0.000 description 6
- 239000002151 riboflavin Substances 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- -1 Chlorine ions Chemical class 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000612152 Cyclamen hederifolium Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 208000015669 capillary disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930186364 cyclamen Natural products 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 150000003227 pyridoxines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Description
本発明は毛髪用育成剤に関するものである。
本発明は人胎盤抽出物を育毛、白毛防止等の育
毛剤として使用せんとするものである。
従来人胎盤抽出物は皮膚に対する賦活化作用を
有するものとして皮膚治療剤として創傷に対する
修復促進剤を用いられきりきず、火傷治療に使用
されていることは公知である。そして最近ではし
み、色黒、等の色素沈着に対する治療或いは美容
剤として使用されている。
然し乍ら従来の人胎盤抽出物の使用方法として
はクリーム、乳剤中に含有せしめこれを皮膚表面
に塗布することにより、皮膚表面からの自然吸収
を目指したものであるため、吸収効率は悪くその
効果を充分に発揮できなかつた。
更に人胎盤抽出物を育毛、その他の毛髪用育成
剤として使用したものは従来存在していない。
そこで本発明に於ては人胎盤抽出物を単に皮膚
上に塗布し自然吸収に委ねるのでなく極めて皮膚
吸収性の大なる物質と結合使用することにより養
毛に大なる影響を有する毛乳頭、毛母細胞等に急
速に到達せしめ直ちに強力な賦活化作用を与えん
とするものである。
以下本発明について詳細に説明すると、胎盤は
常法に従い水洗後ミンチにかけ、脱血した後アセ
トン水及び塩酸混合液に浸し室温で抽出し、後抽
出液に4〜5倍容量のアセトンを添加し析出した
沈澱を過しアセトンで洗滌してデシケーター中
塩化カルシウム上で乾燥する。これは蛋白を含有
しステロイトを含有しない。
又他の胎盤基材の製造方法として胎盤を生理食
塩水で洗滌し脱血し低温代謝を行なつた後ミンチ
にかけ水浴上にて加熱し蛋白質を凝固させ塩酸液
に浸しペプシンを加えて分解させ遠心分離により
上澄より塩酸中のクロールイオンを除去し沈渣よ
りも再び塩酸で加水分解処理し、水浴上で加熱し
塩酸を除去し前記上澄と同様に処理して溶液を得
る。
植物抽出物はトラガントゴム、サポニン含有物
質例えばマロニエ、シクラメン又大豆ルツエルン
等の植物たん白を含有する植物から得る。
この植物抽出物はその粉末をソーダの如き炭酸
塩を加えて十分に混ぜ合せ十分な乳漿を加えると
乳漿構成部分が植物抽出粉末と結合して軟膏が形
成される。
これら形成物質は細胞に対する浸透力が極めて
大である。これらの無脂肪性基材に前記胎盤抽出
物を加え夫々の使用態様に応じて軟膏タイプ、ロ
ーシヨンタイプ等適宜形成させる。
上記の無脂肪性基材に胎盤抽出物を加えたもの
に最近パーキンソン氏病の治療薬として使われ、
その副作用の一つに多毛が問題となつている3,
4−ジオキシフエニール−L−アラニン、所謂L
ドーパを加えるのもよい。このドーパは酵素チロ
シナーゼが肝臓及びメラニン形成細胞でチロシン
への水酸化に作用して形成されるアミノ酸で、該
ドーパは芳香族アミノ酸デカルボキシラーゼによ
つて脱炭酸を受けメラニン形成の中間物たるドー
パミンを形成する。
以下実施例につき説明する。
実施例 1−1
常法により得られた胎盤抽出物 10部(重量部)
乳 漿 85部
ピリドキシン 1部
アスコルビン酸 2部
ビタミンEアセテート 2部
以上の材料をよく配合して水溶性溶液が得られ
る。この溶液を頭部地肌によくすり込み使用す
る。胎盤抽出物、乳漿の皮膚への浸透性により胎
盤抽出物自体の毛乳頭、毛母細胞等への賦活作用
と同時に他のピリドキシンの生体内で活性化した
リン酸エステルの作用によりアミノ酸脱炭酸酵素
及びアミノ基転移酵素の補酵素として、生体内の
タンパク質の代謝に重要な役割を果し、脱毛を予
防する。又毛細血管障害、貧血、壊血病等に効果
のあるアスコルビシ酸の作用により毛髪に艶を与
え皮膚への浸透吸収性、新陳代謝および末梢循環
の改善や促進効果、皮膚の保護作用がある。ビタ
ミンEアセテートにより末梢血管を拡張させ血行
を促進させアスコルビン酸とビタミンEとを併用
させる事によつて当溶液の酸化を防止した。
本実施例を用いて実施した具体例について次の
如きデータを得た。
The present invention relates to a hair growth agent. The present invention aims to use a human placenta extract as a hair growth agent for hair growth, hair graying prevention, and the like. It is well known that human placenta extract has been used as a skin treatment agent as a wound repair accelerator because it has an activating effect on the skin, and has been used in the treatment of burns. Recently, it has been used as a treatment for pigmentation such as age spots and dark skin, or as a cosmetic agent. However, the conventional method of using human placenta extract is to include it in a cream or emulsion and apply it to the skin surface, aiming for natural absorption from the skin surface, which has poor absorption efficiency and reduces its effectiveness. I couldn't perform to my full potential. Furthermore, there have been no products that use human placenta extracts as hair growth or other hair growth agents. Therefore, in the present invention, human placenta extract is not simply applied to the skin and left to natural absorption, but is used in conjunction with a substance that is highly absorbable to the skin, which has a great effect on hair growth. The aim is to reach the mother cells rapidly and immediately exert a strong activating effect. To explain the present invention in detail below, the placenta is washed with water and minced according to a conventional method, and after blood is removed, it is immersed in a mixture of acetone water and hydrochloric acid and extracted at room temperature, and 4 to 5 times the volume of acetone is added to the extracted solution. The precipitate that has separated out is filtered, washed with acetone, and dried over calcium chloride in a desiccator. It contains protein and no steroids. Another method for producing placenta substrates is to wash the placenta with physiological saline, remove blood, and perform low-temperature metabolism, then mince it and heat it on a water bath to coagulate the proteins, soak it in hydrochloric acid solution, and add pepsin to decompose it. Chlorine ions in hydrochloric acid are removed from the supernatant by centrifugation, and the precipitate is hydrolyzed again with hydrochloric acid, heated on a water bath to remove the hydrochloric acid, and treated in the same manner as the supernatant to obtain a solution. Plant extracts are obtained from plants containing plant proteins such as gum tragacanth, saponin-containing substances such as horse chestnut, cyclamen or soybean lucerne. When the powder of this plant extract is thoroughly mixed with a carbonate such as soda and sufficient whey is added, the whey component is combined with the plant extract powder to form an ointment. These forming substances have extremely high permeability to cells. The above-mentioned placenta extract is added to these fat-free base materials to form an ointment type, lotion type, etc. depending on the usage mode. The above fat-free base material with placenta extract added has recently been used as a treatment for Parkinson's disease.
One of the side effects is hirsutism, which is a problem3.
4-Dioxyphenyl-L-alanine, so-called L
It is also good to add dopa. Dopa is an amino acid that is formed when the enzyme tyrosinase hydroxylates it to tyrosine in the liver and melanocytes. Dopa is decarboxylated by aromatic amino acid decarboxylase to produce dopamine, an intermediate in melanin formation. Form. Examples will be explained below. Example 1-1 Placenta extract obtained by conventional method 10 parts (parts by weight) Whey 85 parts Pyridoxine 1 part Ascorbic acid 2 parts Vitamin E acetate 2 parts A water-soluble solution can be obtained by mixing the above materials well. . Use this solution by thoroughly rubbing it into the skin of your head. Due to the permeability of placenta extract and whey into the skin, the placenta extract itself activates the dermal papilla, hair matrix cells, etc. At the same time, amino acids are decarboxylated by the action of the phosphate ester activated in vivo of other pyridoxines. As a coenzyme for enzymes and aminotransferases, it plays an important role in protein metabolism in the body and prevents hair loss. In addition, ascorbic acid, which is effective against capillary disorders, anemia, scurvy, etc., gives shine to the hair, improves and promotes permeation and absorption into the skin, metabolism and peripheral circulation, and protects the skin. Vitamin E acetate dilated peripheral blood vessels to promote blood circulation, and the combination of ascorbic acid and vitamin E prevented oxidation of the solution. The following data were obtained for a specific example implemented using this example.
【表】
実施例 1−2
常法により得られた胎盤抽出物 10部
乳 漿 84部
リボフラビン 1部
ピリドキシン 1部
アスコルビン酸 2部
ビタミンEアセテート 2部
前記溶液にリボフラビンを加え毛髪の新陳代謝
を高めた。
実施例 1−3
常法により得られた胎盤抽出物 10部
乳 漿 82.96部
ピリドキシン 1部
リボフラビン 1部
トリプトフアン 1部
アスコルビン酸 2部
ビタミンEアセテート 2部
エチニルエストラジオール 0.04部
上記エチニルエストラジオールは合成エストロ
ンでありこれを加える事によつて特に典型禿に有
効である。
実施例 1−4
常法により得られた胎盤抽出物 10部
乳 漿 87.45部
ピリドキシン 1部
リボフラビン 1部
コバラミン 0.5部
プレドニゾロン 0.05部
上記プレドニゾロンは合成副腎皮質ホルモンで
円形脱毛症の薬としては既に有名である。
実施例 1−5
常法により得られた胎盤抽出物 10部
ゼロール(商品名.ドイツ メルツ社製)
84.45部
ピリドキシン 1部
リボフラビン 1部
コバラミン 0.5部
ビタミンEアセテート 2部
トリプトフアン 1部
プレドニゾロン 0.05部
上記ゼロールはドイツ.メルツ社製乳漿の商品
名である。コバラミン(ビタミンB12)は神経組
織の機能低下に有効である。
実施例 2−1
トラガント粉末300g、ソーダー粉末3gをよ
く撹拌し10の乳漿を加え250gの硼酸を添加し
て軟膏状物を得る。
上記軟膏状物(植物抽出蛋白質より精製した無脂
肪性基材) 85部
常法により得られた胎盤抽出物 10部
ピリドキシン 1部
アスコルビン酸 2部
ビタミンEアセテート 2部
以上をよく撹拌して軟膏を得る。
上記軟膏状物は皮膚細胞に働き、毛孔の開大と
血行刺載作用が強い。その他は実施例(1−1)
と同様である。
本実施例を用いて実施した具体例について次の
如きデータを得た。[Table] Example 1-2 Placenta extract obtained by conventional method 10 parts whey 84 parts riboflavin 1 part pyridoxine 1 part ascorbic acid 2 parts vitamin E acetate 2 parts Riboflavin was added to the above solution to increase hair metabolism. . Example 1-3 Placenta extract obtained by conventional method 10 parts whey 82.96 parts pyridoxine 1 part riboflavin 1 part tryptophan 1 part ascorbic acid 2 parts vitamin E acetate 2 parts ethinyl estradiol 0.04 part The above ethinyl estradiol is synthetic estrone. By adding this, it is especially effective for typical baldness. Example 1-4 Placenta extract obtained by conventional method 10 parts whey 87.45 parts pyridoxine 1 part riboflavin 1 part cobalamin 0.5 part prednisolone 0.05 part The above prednisolone is a synthetic adrenocortical hormone and is already well-known as a drug for alopecia areata. be. Example 1-5 Placenta extract obtained by conventional method 10 parts Zerol (trade name, manufactured by Merz, Germany)
84.45 parts pyridoxine 1 part riboflavin 1 part cobalamin 0.5 parts vitamin E acetate 2 parts tryptophan 1 part prednisolone 0.05 parts The above Zerol is from Germany. It is the trade name of whey manufactured by Merz. Cobalamin (vitamin B 12 ) is effective in reducing the function of nervous tissue. Example 2-1 300 g of tragacanth powder and 3 g of soda powder are thoroughly stirred, 10 g of whey is added thereto, and 250 g of boric acid is added to obtain an ointment. The above ointment (fat-free base material purified from plant extract protein) 85 parts Placenta extract obtained by conventional method 10 parts Pyridoxine 1 part Ascorbic acid 2 parts Vitamin E acetate 2 parts Stir the above well to make the ointment. obtain. The above ointment acts on skin cells and has a strong effect of dilating pores and stimulating blood circulation. Others are Example (1-1)
It is similar to The following data were obtained for a specific example implemented using this example.
【表】
実施例 2−2
植物抽出蛋白質より精製された無脂肪性基剤84部
常法により得られた胎盤抽出物 10部
リボフラビン 1部
ピリドキシン 1部
アスコルビン酸 2部
ビタミンEアセテート 2部
実施例 3−1
実施例2−1の軟膏状物 81部
常法により得られた胎盤抽出物 10部
Lドーパー 5部
パレトテレ酸カルシウム 2部
ニコチン酸 1部
サリチル酸フエニル 1部
Lドーパーを加えることにより、その頭皮への
浸透が他の胎盤処理剤、植物抽出部と乳漿により
形成される無脂肪性基材の浸透力により運行され
て強力に作用せしめられる。
本実施例を用いて実施した具体例について次の
如きデータを得た。[Table] Example 2-2 Fat-free base purified from plant extract protein 84 parts Placenta extract obtained by conventional method 10 parts Riboflavin 1 part Pyridoxine 1 part Ascorbic acid 2 parts Vitamin E acetate 2 parts Example 3-1 Ointment of Example 2-1 81 parts Placenta extract obtained by conventional method 10 parts L-Dopa 5 parts Calcium paretoterate 2 parts Nicotinic acid 1 part Phenyl salicylate 1 part By adding L-Dopa, the Penetration into the scalp is facilitated by the penetrating power of the non-fat base material formed by other placenta treatment agents, plant extracts and whey, making it a powerful agent. The following data were obtained for a specific example implemented using this example.
Claims (1)
えこれを一般育毛料基材に配合してなる毛髪用育
成剤。 2 常法により精製された胎盤抽出物に乳漿を加
えこれに植物抽出蛋白質より精製した無脂肪性基
材を添加し一般育毛料基材と配合してなる毛髪用
育成剤。 3 乳漿及び植物抽出蛋白質より精製した無脂肪
性基材に胎盤製剤を加えこれに3,4−ジオキシ
フエニール−L−アラニンを加えてなる毛髪用育
成剤。[Scope of Claims] 1. A hair growth agent prepared by adding whey to a placenta extract purified by a conventional method and blending the same into a general hair growth material base material. 2. A hair growth agent made by adding whey to a placenta extract purified by a conventional method, adding thereto a fat-free base material purified from a plant extract protein, and blending the mixture with a general hair growth material base material. 3. A hair growth agent prepared by adding a placenta preparation to a fat-free base material purified from whey and plant extracted proteins, and adding 3,4-dioxyphenyl-L-alanine thereto.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP55178199A JPS57102811A (en) | 1980-12-17 | 1980-12-17 | Growing agent for hair |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP55178199A JPS57102811A (en) | 1980-12-17 | 1980-12-17 | Growing agent for hair |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57102811A JPS57102811A (en) | 1982-06-26 |
JPH0480003B2 true JPH0480003B2 (en) | 1992-12-17 |
Family
ID=16044309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP55178199A Granted JPS57102811A (en) | 1980-12-17 | 1980-12-17 | Growing agent for hair |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57102811A (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60124698A (en) * | 1983-12-09 | 1985-07-03 | ホ−ユ−株式会社 | Dye remover |
IT1186772B (en) * | 1985-10-10 | 1987-12-16 | Crinos Industria Farmaco | COMPOUND WITH PILOSTIMULATING ACTIVITY |
JPH0781140B2 (en) * | 1987-04-09 | 1995-08-30 | 株式会社コーセー | Antioxidant composition |
FR2764504B1 (en) * | 1997-06-11 | 2000-03-10 | Oreal | USE OF A DELIPID MILK DERIVATIVE AS AN AGENT FOR BRAKING HAIR LOSS AND / OR INDUCING AND STIMULATING THEIR GROWTH |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49118818A (en) * | 1973-03-26 | 1974-11-13 | ||
JPS5238035A (en) * | 1975-09-13 | 1977-03-24 | Hoechst Ag | Hair tonic |
JPS5238011A (en) * | 1976-08-28 | 1977-03-24 | Ichimaru Boeki Kk | Method of making stable alcoholic placental extract for use in hair to nics and cosmetics |
JPS52128238A (en) * | 1976-04-15 | 1977-10-27 | Iwao Matsuoka | Prodution method of skin cosmetics for pimple blot and freckle treatment hair growing promotion depilation prevention and dandruff removal |
-
1980
- 1980-12-17 JP JP55178199A patent/JPS57102811A/en active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49118818A (en) * | 1973-03-26 | 1974-11-13 | ||
JPS5238035A (en) * | 1975-09-13 | 1977-03-24 | Hoechst Ag | Hair tonic |
JPS52128238A (en) * | 1976-04-15 | 1977-10-27 | Iwao Matsuoka | Prodution method of skin cosmetics for pimple blot and freckle treatment hair growing promotion depilation prevention and dandruff removal |
JPS5238011A (en) * | 1976-08-28 | 1977-03-24 | Ichimaru Boeki Kk | Method of making stable alcoholic placental extract for use in hair to nics and cosmetics |
Also Published As
Publication number | Publication date |
---|---|
JPS57102811A (en) | 1982-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000191498A (en) | Collagen production facilitative agent and preparation for external use for skin | |
EP0771555B1 (en) | Agent for external application with nutrient and protective properties | |
CA1243957A (en) | Compositions for cosmetic, health- and body- preserving use | |
JPH04208214A (en) | Hair dye for hair, its production and method for dyeing hair | |
JPH0480003B2 (en) | ||
KR20120037071A (en) | Treatment composition of human hair | |
JPS6391315A (en) | Trichogenic promoter | |
JPS6156118A (en) | Hair growing cosmetic | |
Kaye | Observations on the Behaviour of a Substance giving the Nitroprusside reaction in Skin and in Hair | |
JPS59204121A (en) | Remedy for gray hair | |
JPS63150210A (en) | Hair-tonic cosmetic | |
JP3045613B2 (en) | Hair restoration cosmetics | |
JPH0525017A (en) | Skin improving composition and hair nourishing composition | |
Rothman et al. | The physiology of the skin | |
JP3390549B2 (en) | Skin cosmetics | |
JPS60199810A (en) | Hair tonic cosmetic | |
JP2994993B2 (en) | Hair restoration cosmetics | |
JPH1135431A (en) | Extraction of aloe medicinal ingredient and hair grower | |
KR20030000708A (en) | Preparations to promote hair growth and method for producing thereof | |
JPH0699287B2 (en) | Hair growth promotion, hair growth, hair discoloration | |
JPH049320A (en) | Whitening cosmetic | |
JP2004250395A (en) | Bioactive composition | |
JPH02276561A (en) | Tea for regrowing hair | |
JP2006028045A (en) | Cosmetic having depilation-promoting action | |
JPH0248512A (en) | Hair tonic |